<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7794731</article-id><article-id pub-id-type="pmid">33396845</article-id><article-id pub-id-type="doi">10.3390/molecules26010137</article-id><article-id pub-id-type="publisher-id">molecules-26-00137</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Curative Effect of Catechin Isolated from <italic>Elaeagnus Umbellata</italic> Thunb. Berries for Diabetes and Related Complications in Streptozotocin-Induced Diabetic Rats Model</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4289-3970</contrib-id><name><surname>Nazir</surname><given-names>Nausheen</given-names></name><xref ref-type="aff" rid="af1-molecules-26-00137">1</xref><xref rid="c1-molecules-26-00137" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4528-8517</contrib-id><name><surname>Zahoor</surname><given-names>Muhammad</given-names></name><xref ref-type="aff" rid="af1-molecules-26-00137">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2860-467X</contrib-id><name><surname>Ullah</surname><given-names>Riaz</given-names></name><xref ref-type="aff" rid="af2-molecules-26-00137">2</xref></contrib><contrib contrib-type="author"><name><surname>Ezzeldin</surname><given-names>Essan</given-names></name><xref ref-type="aff" rid="af3-molecules-26-00137">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2912-3173</contrib-id><name><surname>Mostafa</surname><given-names>Gamal A. E.</given-names></name><xref ref-type="aff" rid="af3-molecules-26-00137">3</xref><xref ref-type="aff" rid="af4-molecules-26-00137">4</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>McPhee</surname><given-names>Derek J.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-26-00137"><label>1</label>Department of Biochemistry, University of Malakand, Chakdara Dir (L), Khyber Pakhtunkhwa 18800, Pakistan; <email>mohammadzahoorus@yahoo.com</email></aff><aff id="af2-molecules-26-00137"><label>2</label>Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; <email>rullah@ksu.edu.sa</email></aff><aff id="af3-molecules-26-00137"><label>3</label>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; <email>esali@ksu.edu.sa</email> (E.E.); <email>gmostafa@ksu.edu.sa</email> (G.A.E.M.)</aff><aff id="af4-molecules-26-00137"><label>4</label>Micro-Analytical Laboratory, Applied Organic Chemistry Department, National Research Center, Dokki, Cairo 12622, Egypt</aff><author-notes><corresp id="c1-molecules-26-00137"><label>*</label>Correspondence: <email>nausheen.nazir@uom.edu.pk</email>; Tel.: +92-341-6062388</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2021</year></pub-date><volume>26</volume><issue>1</issue><elocation-id>137</elocation-id><history><date date-type="received"><day>01</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>In this study, catechin (CTN) isolated from <italic>Elaeagnus umbellata</italic> was evaluated for in vitro antioxidant potential and inhibition of carbohydrate digestive enzymes (&#x003b1;-amylase and &#x003b1;-glucosidase). The compound was also tested for its in vivo antidiabetic potential using Sprague-Dawley rats as experimental animals. The effects of various doses of catechin in STZ (Streptozotocin) induced diabetic rats on fasting blood glucose level, body weight, lipid parameters, hepatic enzymes, and renal functions were evaluated using the reported protocols. The CTN exhibited the highest percent antioxidant for free radical scavenging activity against DPPH and ABTS free radicals, and inhibited the activity of carbohydrate digestive enzymes (with percent inhibition values: 79 &#x000b1; 1.5% &#x003b1;-amylase and 80 &#x000b1; 1.1% &#x003b1;-glucosidase). Administration CTN and standard glibenclamide significantly decreased the fasting blood glucose level and increased the body weight in STZ-induced diabetic rats. CTN significantly decreased the different lipid parameters, hepatic, and renal function enzyme levels along with Hb1c level in diabetic rats, while significantly increasing the high-density lipoprotein (HDL) level with values comparable to the standard glibenclamide. Further, the altered levels of glutathione and lipid peroxides of liver and kidney tissues were restored (by CTN) to levels similar to the control group. CTN significantly increased the antioxidant enzyme activities, total content of reduced glutathione, and reduced the malondialdehyde (MDA) level in rat liver and kidney tissues homogenates, and also corrected the histopathological abnormalities, suggesting its antioxidant potential.</p></abstract><kwd-group><kwd><italic>Elaeagnus umbellata</italic></kwd><kwd>catechin</kwd><kwd>streptozotocin</kwd><kwd>hyperglycemia</kwd><kwd>hyperlipidemia</kwd><kwd>antioxidant enzymes</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-26-00137"><title>1. Introduction</title><p>Type 2 diabetes mellitus (T2DM) is a metabolic disorder that increases glucose level in blood which ultimately reduces life expectancy, diminishes life quality, and finally leads to mortality and morbidity [<xref rid="B1-molecules-26-00137" ref-type="bibr">1</xref>]. Around 25% of the world&#x02019;s population in the developing and developed countries are suffering from diabetes mellitus. To decrease the burden of glucose and related complications in diabetes, glycemic control is important from a clinical point of view [<xref rid="B2-molecules-26-00137" ref-type="bibr">2</xref>]. DM is considered as a major chronic disease after cancer and cardiovascular diseases in human, caused either due to insufficient insulin secretion by pancreatic islet cells of Langerhans or due to insulin resistance that leads to hyperglycemia [<xref rid="B3-molecules-26-00137" ref-type="bibr">3</xref>]. Increase in blood glucose is associated with the activities of two intestinal enzymes; &#x003b1;-amylase and &#x003b1;-glucosidase that causes the degradation of carbohydrates into disaccharides and finally to monosaccharide. Plasma glucose can be regulated by inhibiting these two enzymes [<xref rid="B4-molecules-26-00137" ref-type="bibr">4</xref>] as DM is associated with hyperlipidemia due to impairments in metabolic pathways [<xref rid="B5-molecules-26-00137" ref-type="bibr">5</xref>].</p><p>Reactive oxygen species (ROS) oxidizes the biologically important macromolecules, such as proteins, lipids, and nucleic acids, thus initiating structural and functional alterations in these molecules. Lipid oxidation produces a secondary product called malondialdehyde (MDA). Lipid peroxidation is a valuable target in the evaluation of oxidative stress and related complications because the hydroxyl radical produced is the most reactive form of ROS that can initiate lipid peroxidation by attacking polyunsaturated fatty acids. Oxidative stress is the major cause of diabetes mellitus and associated comorbidities [<xref rid="B6-molecules-26-00137" ref-type="bibr">6</xref>].</p><p>Glycated haemoglobin (HbA1c) is a useful test that plays a central role in the diagnosis, prevention, and monitoring of diabetes. The benefit of glycated haemoglobin testing is that it does not vary noticeably with time and can therefore be done at any time of the day and also provides better reproducibility than glucose testing. HbAc1 testing provides instant results that are very important for therapeutic purpose and also for lifestyle interventions and improve overall diabetes care and control [<xref rid="B7-molecules-26-00137" ref-type="bibr">7</xref>]. The American Diabetes Federation uses an HbA1c value greater than 6.5% as a definite diagnosis of diabetes mellitus [<xref rid="B8-molecules-26-00137" ref-type="bibr">8</xref>]. Furthermore, HbA1c levels between 5.7% and 6.4% correspond to people with pre-diabetes who are at higher risk of developing DM.</p><p>According to the world health organization (WHO) evaluation report, medicinal plants are of great importance as they are sources of safer modern and effective drugs, with comparatively low side effects. Furthermore, pharmacological and chemical investigations are necessary to explore potential antidiabetic agents from plants sources [<xref rid="B9-molecules-26-00137" ref-type="bibr">9</xref>]. The ideal aim to control T2DM is an effective control of blood glucose level, HbA1c, hypertension, and hyperlipidaemia [<xref rid="B10-molecules-26-00137" ref-type="bibr">10</xref>].</p><p>Due to the scientific exploration on berries in the recent years they have gained more importance for human beings, as they have rich phytoconstituents and have great health benefits. The key flavonoids found in berries are proanthocyanins, anthocyanin, catechins, and flavonols, while the hydroxylated phenolic acids are cinnamic and benzoic acid that can reduce hyperglycemia through regulation of &#x003b1;-glucosidase and &#x003b1;-amylase enzymes [<xref rid="B11-molecules-26-00137" ref-type="bibr">11</xref>]. Many studies from the literature have revealed that regular consumption of flavonoid rich berries fruit can alleviate type 2 diabetes, ischemic diseases, aging effects, Parkinson&#x02019;s, and Alzheimer&#x02019;s disease [<xref rid="B11-molecules-26-00137" ref-type="bibr">11</xref>]. Many authors have reported the beneficial effects of berries fruits, vegetables and fruits juices that have exhibited positive health benefits, recommending them to be a good source of phytochemicals that could be used for curing type 2 diabetes and associated hypertension [<xref rid="B12-molecules-26-00137" ref-type="bibr">12</xref>]. To properly manage T2DM, further work is needed to isolate potent compounds from medicinal plants with low side effects.</p><p>Among the berried plants, <italic>Elaeagnus umbellata</italic> Thunb, reported as an antidiabetic medicinal plant [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>], is a spiny deciduous shrub belonging to the family <italic>Elaeagnaceae.</italic> The plant is native to South Europe, Central Asia, Japan, China, India, Afghanistan, Azad Kashmir, and Himalayan areas of Pakistan [<xref rid="B14-molecules-26-00137" ref-type="bibr">14</xref>,<xref rid="B15-molecules-26-00137" ref-type="bibr">15</xref>]. Its berries fruit is a big source of antioxidant compounds (lycopene, &#x003b2;-carotene, lutein, phytofuluene, phytoene, &#x003b2;-cryptoxanthin, and &#x003b1;-cryptoxanthin), polyphenols, and vitamin E content (&#x003b1;-tocopherols and &#x003b3;-tocopherols) with therapeutic significances [<xref rid="B16-molecules-26-00137" ref-type="bibr">16</xref>,<xref rid="B17-molecules-26-00137" ref-type="bibr">17</xref>]. Carotenoids and lycopene are the major sources for the astringent flavor of the berries fruits [<xref rid="B18-molecules-26-00137" ref-type="bibr">18</xref>]. Recently, attention has been focused on the relationship between berries fruits and the inhibition of the DM progress.</p><p>Flavonoids are the most potent antioxidant identified in significant amounts in fruit and vegetable. Catechin is one of the most important flavonoids, with a comparatively high antioxidant activity [<xref rid="B19-molecules-26-00137" ref-type="bibr">19</xref>]. Catechins have the beneficial effect of preventing skin damage. Catechins are important ingredients in the tea plant that have exhibited intensive anti-oxidant and other representative physiological activities in experimental animals. They are members of the group of polyphenol compounds found in many medicinal plants. The major sources of catechin are <italic>Camellia sinensis</italic> (<italic>C. sinensis</italic>) and <italic>C. assumica.</italic> Green tea contains 75&#x02013;80% water and polyphenol (flavanols, flavandiols, flavonoid, and phenolic acid) compounds [<xref rid="B19-molecules-26-00137" ref-type="bibr">19</xref>]. Green tea is a popular beverage consumed worldwide for its long history and numerous health benefits due to the presence of various amounts of catechins such as catechin, (&#x02013;)-epigallocatechin-3-gallate, (&#x02013;)-epicatechin-3-gallate, (&#x02013;)-epigallocatechin, and (&#x02013;)-epicatechin. Several investigational studies have indicated that the antioxidant properties of green tea come from the flavonoids. Catechins provide several health advantages by scavenging free radicals thus retarding extracellular matrix degradation induced by ROS, ultraviolet radiation and pollution. The health raising properties of catechins are commonly related to their redox antioxidant capacity rather than to the other molecular activities. Catechins are one of the most important flavonoids, with antioxidant and anti-inflammatory properties rendering them a potent therapeutic for diseases where the mentioned processes are critical negative elements [<xref rid="B20-molecules-26-00137" ref-type="bibr">20</xref>]. A number of scientists have isolated catechin from different plants and evaluated them to be beneficial in controlling oxidative stress, diabetes, high blood pressure, lipid absorption and glucose intolerance induced by a high fat diet [<xref rid="B19-molecules-26-00137" ref-type="bibr">19</xref>,<xref rid="B21-molecules-26-00137" ref-type="bibr">21</xref>,<xref rid="B22-molecules-26-00137" ref-type="bibr">22</xref>].</p><p>The present study was therefore planned to investigate the biological effects of <italic>E. umbellata</italic> berries catechins on blood glucose level, lipid profile, Hb1c level, hepatic and renal functions, antioxidant enzymes, and MDA levels in the STZ-induced diabetic rats.</p></sec><sec sec-type="results" id="sec2-molecules-26-00137"><title>2. Results</title><sec id="sec2dot1-molecules-26-00137"><title>2.1. In Vitro Antioxidant Potential of CTN</title><p>DPPH inhibition potential of CTN were 65 &#x000b1; 1.35***, 50 &#x000b1; 1.1***, 44 &#x000b1; 0.5***, 37 &#x000b1; 0.4***, 31 &#x000b1; 1.0***, and 29 &#x000b1; 1.4*** at concentration 1000, 500, 250, 125, 62.5, and 31.25 &#x000b5;g/mL with their IC<sub>50</sub> values 65&#x000b5;g/mL. While the ABTS free radical scavenging potential of CTN were 59 &#x000b1; 1.5**, 46 &#x000b1; 1.8***, 41 &#x000b1; 0.8***, 36 &#x000b1; 1.4***, 28 &#x000b1; 1.2***, and 21 &#x000b1; 1.5*** at concentration 1000, 500, 250, 125, 62.5, and 31.25 &#x000b5;g/mL with IC<sub>50</sub> values 72&#x000b5;g/mL. The results indicated in <xref ref-type="fig" rid="molecules-26-00137-f001">Figure 1</xref>A,B and <xref ref-type="app" rid="app1-molecules-26-00137">Table S1</xref> indicate that CTN has comparable % inhibition potential of the used free radicals to standard ascorbic acid against (ascorbic acid IC<sub>50</sub>; 30 &#x000b5;g/mL against DPPH and IC<sub>50</sub>; 32 &#x000b5;g/mL against ABTS). The experiments have been performed in three replicates.</p></sec><sec id="sec2dot2-molecules-26-00137"><title>2.2. In Vitro Antidiabetic Potential of CTN</title><p>Highest percent inhibitory potential of diabetic enzyme (&#x003b1;-amylase; 83 &#x000b1; 1.5, &#x003b1;-glucosidase; 85 &#x000b1; 1.1) were exhibited by CTN at highest concentration 1000 &#x000b5;g/mL (<xref ref-type="fig" rid="molecules-26-00137-f001">Figure 1</xref>C,D; <xref ref-type="app" rid="app1-molecules-26-00137">Table S2</xref>). The IC<sub>50</sub> values were calculated by evaluating the plot of % &#x003b1;-amylase and % &#x003b1;-glucosidase enzyme inhibition as a function of CTN concentrations. The IC<sub>50</sub> values for &#x003b1;-amylase and &#x003b1;-glucosidase were 38 and 32 &#x000b5;g/mL respectively. These values are comparable to that of the standard acarbose was used as a positive control which causes percent inhibition 90 &#x000b1; 0.4 and 89 &#x000b1; 0.5 against &#x003b1;-amylase &#x003b1;-glucosidase at maximum concentration of 1000 &#x000b5;g/mL with IC<sub>50</sub> value 30 and 26 &#x000b5;g/mL respectively (<xref ref-type="app" rid="app1-molecules-26-00137">Table S2</xref>).</p></sec><sec id="sec2dot3-molecules-26-00137"><title>2.3. In Vivo Antidiabetic Potential of CTN</title><sec id="sec2dot3dot1-molecules-26-00137"><title>2.3.1. Effect of Various Treatments on Blood Glucose Level</title><p><xref ref-type="fig" rid="molecules-26-00137-f002">Figure 2</xref>A,B depicts the effects CTN in various treatments groups and STZ group on fasting blood glucose level in rats. Treatment with STZ significantly increased fasting blood glucose level in rats of groups II (Diabetic control) on day 1st in comparison to the normal control (group I) group and CTN treated groups IV-IX. Blood glucose level of diabetic rats increased significantly (<italic>p</italic> &#x0003c; 0.001) on days 1, 5, 8, 10, 15, and 21 compared to normal control rats (groups I). In standard glibenclamide (Group III) treated group significantly (<italic>p</italic> &#x0003c; 0.001) decreased in fasting glucose level in blood of diabetic rats was observed (as compared to diabetic control rats on days 10, 15, and 21). Although CTN at lowest dose of 2, 5, and 10 mg/kg body weight exerted a significant effect on blood glucose level in diabetic rats when compared to diabetic control rats but the effect was more pronounced when bioactive compound was administered in high dose range (15, 30 and 50 mg/kg) and fasting blood glucose level of diabetic rats were significantly (<italic>p</italic> &#x0003c; 0.01, <italic>p</italic> &#x0003c; 0.001) decreased. Blood glucose level reduction was observable from the 5th day and onward while the patterns were significantly apparent on days 10 (<italic>p</italic> &#x0003c; 0.05), 15, and 21 (<italic>p</italic> &#x0003c; 0.001).</p></sec><sec id="sec2dot3dot2-molecules-26-00137"><title>2.3.2. Effect of Various Treatments on Body Weight in Diabetic Rats</title><p>Results of various treatments groups on body weight of diabetic rats are presented in <xref ref-type="fig" rid="molecules-26-00137-f002">Figure 2</xref>C,D. There was no significant effect on body weight of diabetic rats on days 1 and 5. However, the weight of diabetic control rats (group II) was significantly decreased on day 15 (<italic>p</italic> &#x0003c; 0.001) and 21 (<italic>p</italic> &#x0003c; 0.001) in comparison to the normal saline control rats (group I). Diabetic rats treated with glibenclamide (5 mg/kg, p.o) has significantly (<italic>p</italic> &#x0003c; 0.001) reversed diabetes-induced decrease in body weight on day 15 and 21 compared to diabetic control rats. Moreover, diabetic rats treated with CTN (15, 30 and 50 mg/kg, p.o) reversed the STZ mediated reduction in body weight and significantly increased the body weight on day 15 (<italic>p</italic> &#x0003c; 0.001) followed by day 21 (<italic>p</italic> &#x0003c; 0.001) when compared to diabetic control rats.</p></sec><sec id="sec2dot3dot3-molecules-26-00137"><title>2.3.3. Effect of Various Treatments on Liver and Renal Functions in STZ-Induced Diabetic Rats</title><p>The activity of hepatic enzymes such as ALP, AST, SGPT, SGOT, and renal functions such as serum creatinine in normal control group, diabetic control group and compound treatment group have been shown in <xref ref-type="fig" rid="molecules-26-00137-f003">Figure 3</xref>. STZ-induced Diabetes in rat considerably increased (<italic>p</italic> &#x0003c; 0.001) the level of liver marker enzymes such as SGPT, SGOT and ALP and renal functions such as serum creatinine and blood urea as compared to the normal control. Administration of standard glibenclamide (5 mg/kg) and CTN (2, 5, 10, 15, 30, and 50 mg/kg body weight) to diabetic rats resulted in significant decrease (<italic>p</italic> &#x0003c; 0.01, <italic>p</italic> &#x0003c; 0.001) in ALP, AST, SGPT, SGOT, serum creatinine, and blood urea levels.</p></sec><sec id="sec2dot3dot4-molecules-26-00137"><title>2.3.4. Effect of Various Treatments on Serum Lipid Profile and Hb1c in Diabetic Rats</title><p><xref ref-type="fig" rid="molecules-26-00137-f004">Figure 4</xref> shows the effects of various treatments on lipid profiles of diabetic rats on day 21. Rats in the diabetic control group (group II) showed significant (<italic>p</italic> &#x0003c; 0.001) increases in plasma lipid parameters TC, TG, LDL, and HbA1c, however a significant (<italic>p</italic> &#x0003c; 0.001) decrease in plasma HDL compared to normal saline control rats (groups I) was observed. Standard glibenclamide (5 mg/kg) has significantly decreased (<italic>p</italic> &#x0003c; 0.001) the plasma TC, TG, and LDL levels in diabetic rats. However, oral administration of CTN (15, 30, and 50 mg/kg, respectively) has significantly decreased (<italic>p</italic> &#x0003c; 0.001) TC, TG, and LDL levels, while significantly increased (<italic>p</italic> &#x0003c; 0.001) HDL cholesterol in diabetic rats was also observed as compared to diabetic control rats.</p></sec><sec id="sec2dot3dot5-molecules-26-00137"><title>2.3.5. Effect of Various Treatments on Glutathione Peroxidase</title><p>Biochemical analysis showed that antioxidant stress marker enzyme levels such as glutathione peroxidase in liver (<xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>A) and kidney (<xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>D) tissue homogenates of STZ-induced diabetic rats were significantly high which were controlled by treatment with berries CTN in STZ-induced diabetic rats suggesting that <italic>E. umbellata</italic> berries possess strong antioxidant proprieties.</p></sec><sec id="sec2dot3dot6-molecules-26-00137"><title>2.3.6. Effect of Various Treatments on Lipid Peroxidation and Concentration of Reduced GSH</title><p><xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref> shows that administration of CTN (2, 5, 10, 15, 30, and 50 mg/kg body weight) has significantly (<italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.00 = 1, <italic>p</italic> &#x0003c; 0.001) reduced MDA level in STZ-induced diabetic rats. The high dose of CTN (50 mg/kg) was more effective as compare to low doses (10 mg/kg and below). CTN treated groups exhibited reduction in lipid peroxidation, observed through significant decrease of MDA level estimated in liver (<xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>B) and kidney (<xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>E) tissue homogenates in comparison to the diabetic control group. Furthermore, a significant increase in the concentration of reduced GSH estimated in liver (<xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>C) and kidney (<xref ref-type="fig" rid="molecules-26-00137-f005">Figure 5</xref>F) tissue homogenates of the CTN treated groups in comparison to diabetic control group was also observed.</p></sec><sec id="sec2dot3dot7-molecules-26-00137"><title>2.3.7. Effect of Various Treatments on Pancreas Histopathology in STZ-Induced Diabetic Rats</title><p>The effect of CTN administered in different doses on pancreas histopathology in STZ-induced diabetic rats is represented in <xref ref-type="fig" rid="molecules-26-00137-f006">Figure 6</xref>. The histological pattern of the pancreas of the normal control group has shown clear lobular architecture (<xref ref-type="fig" rid="molecules-26-00137-f006">Figure 6</xref>A). Islets of Langerhans were of normal diameter and structure, acinar cells were clear with prominent and centrally placed nuclei and interlobular spaces were also visible. The central cellular integrity and lobular structure of pancreas was retained. The effect of CTN on pancreas histopathology in STZ-induced diabetic rats indicates that a normal histological pattern of the pancreas was shown by the normal control group rats, as presented in <xref ref-type="fig" rid="molecules-26-00137-f006">Figure 6</xref>. Acinar cells were clear with prominent and centrally placed nuclei, and interlobular spaces were also visible. The islet of Langerhans was of normal diameter and structure and the overall cellular integrity and architecture was maintained. The pancreas of Diabetic control group rats (<xref ref-type="fig" rid="molecules-26-00137-f006">Figure 6</xref>B) showed a typical histological pattern with slight grade of congestion and dilated blood vessels with inflammatory cell infiltration. The diameter of islet of Langerhans was decreased with decreased cellular density. Shrined and pyknotic nuclei are also visible in the center of the islet. The boundary of the endocrine and exocrine portion of the pancreas was also indistinct. The presence of inflammatory cells can be observed in connective tissue spaces as well. The histological pattern of the pancreas of group III rats were treated with glibenclamide 5 mg/kg/orally (<xref ref-type="fig" rid="molecules-26-00137-f006">Figure 6</xref>C). The pancreatic tissue of this group of rats did not show any violation from the normal histological pattern during experimental period. No congestion or deterioration was observed in the in acinar cells. There was no reduction in the diameter of Islet of Langerhans and nuclei were also centrally placed. The boundary of endocrine and exocrine portion of pancreas was distinct and overall normal histological pattern was retained. The histological pattern of groups IV and V treated with CTN (2, 5 mg/kg/orally) did not show restoration of pancreatic tissue (<xref ref-type="fig" rid="molecules-26-00137-f006">Figure 6</xref>D,E). The diameter of the islet of Langerhans was declined with reduced cellular mass and the nuclei were not properly aligned. The presence of inflammatory cells and pyknotic nuclei were also observed to some extent, which showed that the CTN with dose 2, 5 mg/kg/orally was not effective to treat STZ-induced diabetes. Group VI-VII (CTN 10, 15 mg/kg/orally) has shown a little bit restoration of histological architecture of pancreas (<xref ref-type="fig" rid="molecules-26-00137-f006">Figure 6</xref>F,G). The size and number of Islet of Langerhans were recovered with low grade rejuvenation but still the distinction of septa between the islets and acinar is not prominent. The presence of inflammatory cells was negligible and the overall cytoplasmic integrity was retained to some extent. The groups VIII&#x02013;IX (30 and 50 mg/kg/orally) show normal histological pattern of the pancreas with clear lobular architecture (<xref ref-type="fig" rid="molecules-26-00137-f006">Figure 6</xref>H,I). The isslet of Langerhans was of normal diameter and structure, acinar cells were clear with prominent and centrally placed nuclei and interlobular spaces were also visible. The central cellular integrity and lobular structure of the pancreas was also retained. These results showed that the maximum efficacy of CTN to treat diabetes is obtained at a doses of 30 and 50 mg/kg/orally in STZ-induced diabetes.</p></sec></sec></sec><sec sec-type="discussion" id="sec3-molecules-26-00137"><title>3. Discussion</title><p>Diabetes is the world&#x02019;s fastest growing disease with a high prevalence of morbidity and mortality. This chronic disease is not treatable but can be managed. Consumption of traditional plant medicines and natural product have been in use for centuries to improve diabetic symptoms. In Pakistan, berries fruits are used for the treatment of various disorders including the management of diabetes [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>]. So, keeping in view the medicinal and pharmacological importance of <italic>E. umbellata</italic> fruit berries in controlling diabetes the current study was designed to isolate berries catechin and investigate its antidiabetic potential.</p><p>Glucose is the end product of carbohydrate metabolism that is most readily absorbed into blood and presented as an increase in post-prandial hyperglycemic condition. Inhibition of carbohydrate digesting enzymes; &#x003b1;-amylase and &#x003b1;-glucosidase can delay the absorption of glucose and consequently results in a decline of post prandial hyperglycemic state. Our results were in line with reported study carried out on <italic>Ononis angustissima</italic> aqueous extract/fraction that exhibited strong inhibitory activity on carbohydrate digestive enzymes; &#x003b1;-amylase and &#x003b1;-glucosidase [<xref rid="B23-molecules-26-00137" ref-type="bibr">23</xref>]. In our results berries catechin exhibited strong dose dependent inhibition of digestive enzymes. A similar dose dependent inhibition of &#x003b1;-amylase and &#x003b1;-glucosidase has been observed previously in case of extract/fractions of <italic>Elaeagnus umbellata</italic> [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>] and <italic>Salacia oblonga</italic> [<xref rid="B24-molecules-26-00137" ref-type="bibr">24</xref>].</p><p>The isolated catechin significantly inhibited &#x003b1;-amylase and &#x003b1;-glucosidase enzymes indicating its antihyperglycemic effects, which is in agreement with reported studies on other phenolic compounds [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>]. The obtained data confirmed that the use of catechin (2, 5, 10, 15, 30 and 50 mg/kg) and glibenclamide significantly decreased glucose levels in STZ-induced diabetic rats. Studies have shown [<xref rid="B25-molecules-26-00137" ref-type="bibr">25</xref>] that the use of glibenclamide increases the sensitivity of &#x003b2;-cells and activates insulin synthesis and secretion from the &#x003b2;-cells of the pancreas that might be associated with its anti-hyperglycemic activity. Furthermore, catechin has protective effects on the major tissues including liver, kidney, and pancreas thus have a minimizing effect of diabetes associated complications [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>].</p><p>It was also observed that catechin in the dose of 30 and 50 mg/kg body weight can significantly improve the adverse metabolic effects in the serum of animals treated with streptozotocin. STZ-induced diabetic rats treated with catechin have significantly reduced serum glucose level, improved lipid profiles (TC, TGs, LDL, HDL, and cholesterol), liver profiles (SGPT, SGOT, ALP, AST, and serum creatinine), and body weight. The results of the current study confirm the previous outcomes reported by other researchers that catechin has significantly improved STZ damages in rats [<xref rid="B21-molecules-26-00137" ref-type="bibr">21</xref>,<xref rid="B22-molecules-26-00137" ref-type="bibr">22</xref>,<xref rid="B26-molecules-26-00137" ref-type="bibr">26</xref>]. The current study also indicates the improvement in oxidative stress in the STZ diabetic rats that might be due to strong antioxidant potential of catechin against DPPH and ABTS free radicals. Our results are in line with the reported study that hyperglycemia in STZ treated group is due to the cytotoxic effect of STZ on insulin secreting &#x003b2;-cells of pancreas that are also accompanied with an increase in lipid peroxidation. Thus, destruction of pancreatic &#x003b2;-cells is related to the locally and systemically induced oxidative stress [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>,<xref rid="B27-molecules-26-00137" ref-type="bibr">27</xref>,<xref rid="B28-molecules-26-00137" ref-type="bibr">28</xref>,<xref rid="B29-molecules-26-00137" ref-type="bibr">29</xref>].</p><p>A significant increase in lipid parameters levels such as TC, TGs, LDL, and cholesterol was observed while at the same time a significant decrease of HDL cholesterol in STZ-induced diabetic rats was also evident in comparison to normal control group. These results were in line with other previous studies where it has been observed that increase in circulating free fatty acids enhances hepatic TGs production. High TGs content associated with formation of an atherogenic dyslipidaemia consisting of an elevation in high TG content, low HDL cholesterol and increased LDL or apo lipoprotein-B [<xref rid="B19-molecules-26-00137" ref-type="bibr">19</xref>,<xref rid="B30-molecules-26-00137" ref-type="bibr">30</xref>]. Epidemiological studies indicated that regular intake of more than two cups of green tea and its catechin have been shown to ameliorate oxidative stress, hyperlipidemia and lower the concentration of TC and LDL, which has also been demonstrated in the performed meta-analysis of randomized clinical trials [<xref rid="B31-molecules-26-00137" ref-type="bibr">31</xref>].</p><p>It was also observed that STZ-induced diabetic rats showed a considerable increase in the levels of hepatic enzymes such as SGPT, SGOT, ALP, AST, and serum creatinine. The improvement of STZ effects in rats after treatment with catechin might indicate a protective effect of it against STZ function due to decrease in oxygen free radicals production and also increase in antioxidant content. In the present investigation, SGPT, SGOT, ALP, AST, and serum creatinine activities were significantly reduced in catechin treated diabetic rats in comparison to the untreated diabetic rats which were in line with previous findings [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>,<xref rid="B31-molecules-26-00137" ref-type="bibr">31</xref>]. It has been demonstrated in a related study the hypoglycemic and antioxidant activity of catechin in the STZ-induced diabetic rat are also associated with reduction in lipid peroxidation [<xref rid="B26-molecules-26-00137" ref-type="bibr">26</xref>].</p><p>The observed high level Hb1Ac; the key biomarker of diabetes in STZ-induced diabetic rat model also in line with reported studies [<xref rid="B8-molecules-26-00137" ref-type="bibr">8</xref>,<xref rid="B32-molecules-26-00137" ref-type="bibr">32</xref>]. The HbA1c value may greatly be affected by variations in the amount of glucose that enters the erythrocyte membrane, either to increase the rate of glycosylation or change the lifespan of erythrocytes resulting in an increase or decrease in HbA1c value, respectively [<xref rid="B8-molecules-26-00137" ref-type="bibr">8</xref>].</p><p>Among phenolic compounds; flavonoids have been reported as scavenger of free radicals that shows strong antioxidant activity by donating hydrogen group. Catechin also exhibits its antioxidant and free radicals scavenging activity through hydrogen donating ability in STZ-diabetic rats. Glutathione peroxidase is the key antioxidant enzyme which plays a major role in oxidative damage against oxidative stress induced by free radicals. The current study showed that streptozotocin administration in rat&#x02019;s results in decreased activities of glutathione peroxidase which is a validation of the other investigations. Catechin treatments of diabetic rats cause reduction in free radical generation and lipid peroxidation thus elevating antioxidant defence. Antioxidant activity of catechin has been validated in several other studies as well [<xref rid="B19-molecules-26-00137" ref-type="bibr">19</xref>,<xref rid="B26-molecules-26-00137" ref-type="bibr">26</xref>].</p><p>Streptozotocin causes lipid peroxidation and increases the concentration of MDA in hepatocytes. Increases in MDA level is an important indicator of tissue damages. Administration of berries catechin (2, 5, 10, 15, 30, and 50mg/kg body weight) markedly reduced the MDA content near to normal that has been validated by other studies on plant extracts [<xref rid="B6-molecules-26-00137" ref-type="bibr">6</xref>]. Antioxidant enzymes such as glutathione peroxidase are involved in the reduction of free radical and oxidative stress. STZ intoxicated rats exhibited a decrease in the total content of reduced GSH level, GPx activities, and elevated MDA level. Increased MDA level have been shown to be an important marker for in vivo lipid peroxidation. Oxidative stress results from a marked imbalance between free radical production and elimination by antioxidant system. Furthermore, berries catechin (2, 5, 10, 15, 30, and 50 mg/kg body weight) significantly (<italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.01, <italic>p</italic> &#x0003c; 0.001) increased GPx activities and the content of reduced GSH in both liver and kidney homogenates, and decreased MDA level. Such regulation of oxidative stress markers by the catechin may be well correlated with previous reports, where catechin have antioxidant and free radical scavenging ability [<xref rid="B31-molecules-26-00137" ref-type="bibr">31</xref>].</p><p>A significant decrease in body weight was also observed after 21 days in STZ- induced diabetic rats. It is majorly due to decrease of carbohydrate reserve as an energy source and fats catabolism during diabetic conditions that usually cause excessive break down of tissue protein that leads to loss in body weight. However, oral administration of <italic>E. umbellata</italic> berries catechin at a dose range of 30 and 50 mg/kg body weight for 21 days to diabetic rats brings a pronounced increase in body weight. Similar effects have also been reported in other studies where restoration in body weight with extract of <italic>Ginkgo biloba</italic> [<xref rid="B33-molecules-26-00137" ref-type="bibr">33</xref>], <italic>Afzelia africana</italic> [<xref rid="B34-molecules-26-00137" ref-type="bibr">34</xref>], and <italic>Elaeagnus umbellata</italic> [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>] have been recorded in STZ-induced diabetic rats. These results designate that <italic>E. umbellata</italic> berries possessed the ability of body weight restoration and management of glucose levels.</p><p>Histopathological analysis clearly showed improvement in pancreas section of the treated groups (catechin treated groups) when compared to STZ-induced diabetic group. The pancreatic tissue of diabetic rat demonstrated degeneration and vacuolization in the Langerhans&#x02019;s islet cells. The diameter of the islet of Langerhans was decreased with decreased cellular density. Shrined and pyknotic nuclei were also visible in the center of the islet. The boundary of endocrine and exocrine portion of the pancreas was also indistinct, besides decrease in islets size and &#x003b2;-cell number was also observed. This data was in agreement with the study of Ramadan et al. [<xref rid="B35-molecules-26-00137" ref-type="bibr">35</xref>]. Current results indicated that histological pattern of pancreas of groups treated with glibenclamide (5 g/kg/overly) and catechin (15, 30, and 50 mg/kg; p.o) did not show any violation from the normal histological pattern during experimental period. Similar to previous investigations, our study demonstrated that glibenclamide and catechin treatment are useful to increase pancreatic regeneration, number and diameter of islet of Langerhans and an increase in &#x003b2;-cell function after treatment in STZ-induced diabetic rates [<xref rid="B36-molecules-26-00137" ref-type="bibr">36</xref>].</p><p>In conclusion, the current study designated that the anti hyperglycemic and hypolipidemic ability of catechin exhibits a protective effect on various parameters in the STZ induced diabetic rats and helped in relieving the related complications. Based on the results of the histopathological studies of the pancreatic tissue, the anti-diabetic activity of those samples was believed to occur through the mechanism of increasing secretion of healthy pancreatic &#x003b2;-cells. However, more studies are needed for evaluating the exact protective mechanism of catechin for diabetes management and its complications in animal models.</p></sec><sec id="sec4-molecules-26-00137"><title>4. Materials and Methods</title><sec id="sec4dot1-molecules-26-00137"><title>4.1. Chemicals and Reagents</title><p>Antioxidant chemicals such as DPPH, ABTS, and ascorbic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA); while antidiabetic chemicals and reagents such as Type-I &#x003b1;-Glucosidase (Baker Yeast), Type-VI &#x003b1;-amylase (porcine pancreas), PNPG (<italic>p</italic>-nitrophenyl-&#x003b1;-<sc>d</sc>-glucopyranose), streptozotocin were obtained from Sigma Aldrich (Darmstadt, Germany); glucose estimation kits from SD Chek-Gold Germany, and glibenclamide was provided by Sanofi-Aventis-Pharma Pakistan. Chemicals such as Tween-80 (Scharlau-chem., Barcelona, Spain), normal saline solution (Utsoka Pharma, Las Bela Baluchistan, Pakistan), lipid profile tests kits (Human, Hamburg, Germany), and renal profile tests kits, antioxidant enzymes kits (Biomed: Germany; diagnostic) were used in in vivo study. Various solvents such as methanol, <italic>n</italic>-hexane, ethyl acetate, and chloroform (Merck, Darmstadt, Germany) were also used in this study.</p></sec><sec id="sec4dot2-molecules-26-00137"><title>4.2. Plant Material Collection</title><p><italic>E. umbellata</italic> berries fruits were collected from the mountainous regions of District Kalam, Malakand Division, Khyber Pakhtunkhwa, Pakistan, in the month of August and September 2019. The plant specimen was identified at Post Graduate College Swat, Khyber Pakhtunkhwa, Pakistan. Voucher specimen (BGH-UOM-154) were deposited in the Botanical Garden Herbarium, University of Malakand, Pakistan [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>].</p></sec><sec id="sec4dot3-molecules-26-00137"><title>4.3. Extraction, Fractionation and Isolation of Pure Compound</title><p>According to the method presented in a previously published article [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>], the plant extract preparation and fractionation were carried out. About 10 kg of dried berries fruits were crushed through mechanical grinder to obtain fine powders. The extraction was carried out using fruit powder mixed in 80% methanol for two weeks with periodical shaking. The resulting mixture was filtered using muslin cloth followed by Whattman filter paper and the filtrate was dried into a semisolid mass at 45 &#x000b0;C under reduced pressure in the rotary evaporator. Finally the resultant 750 g semisolid mass of extract was solidified in an open air. The resultant methanol extract in the specified amount was dissolved in a mixture (0.5 L) of methanol/water (7:3) and successively extracted by solvent&#x02013;solvent extraction method using different solvents (<italic>n</italic>-hexane, chloroform, ethyl acetate <italic>n</italic>- butanol, and aqueous starting from a low polarity to high. On the basis of in vitro analysis, the result of the chloroform fraction was found as the most active and was further subjected to isolation of bioactive compounds. The chloroform fraction was subjected to silica gel chromatography column with internal diameter of 10 cm packed height 50 cm in solvent system of <italic>n</italic>-hexane and ethyl acetate (3:7) yielded compound 2.5 g (catechin) in pure form. The compound was characterized through different spectroscopic techniques such as FTIR, H-NMR, <sup>13</sup>C-NMR, and Mass spectrometry. The purified compound catechin was screened for in vitro and in vivo antioxidant and antidiabetic activity.</p></sec><sec id="sec4dot4-molecules-26-00137"><title>4.4. Structural Confirmation and Characterization of Isolated Compounds</title><p>The structure of the isolated catechin (2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol) is presented in <xref ref-type="app" rid="app1-molecules-26-00137">Figure S1 (Supplementary file)</xref>. The molecular formula of catechin was determined as C<sub>15</sub>H<sub>14</sub>O<sub>6</sub> by ESIMS and Molar mass (<italic>m</italic>/<italic>z</italic>) is 290.1 g/mol. <sup>1</sup>H-NMR (METHANOL-d<sub>4</sub>,300MHz): &#x003b4; = 6.73&#x02013;6.62, signifies the aromatic protons at 15th, 20th and 21th carbon of the given structure, &#x003b4; = 5.83 (s, 1H) this singlet could be the hydrogen atom at carbon number 11, &#x003b4; = 5.76 (s, 1H) this singlet could be attributed to proton attached with carbon number 8 of the given structure, 4.76 (s, 4H) this broad singlet represents the four protons each one attached as a &#x02013;OH group to the carbon number 6, 9, 16 and 18. &#x00394; = 4.46 (d, <italic>J</italic> = 7.5 Hz, 1H), 3.87 (d, <italic>J</italic> = 5.1 Hz, 1H) this duplet can be precisely represent by a proton attached to the carbon number 2 of the given structure, &#x003b4; = 2.71 ppm (s, 1H) this singlet has been contributed by the protons attached to the carbon number 4 of the given structure (<xref ref-type="app" rid="app1-molecules-26-00137">Figure S2</xref>). <sup>13</sup>C-NMR (METHANOL-d<sub>4</sub>, 75MHz): &#x003b4; = 156.4, 156.2, 155.5, 144.8, 130.8, 118.6, 113.9, 99.4, 94.9, 94.1, 81.5, 67.4, 27.1 ppm (<xref ref-type="app" rid="app1-molecules-26-00137">Figure S3</xref>). The EIMS and FTIR spectrum is represented in <xref ref-type="app" rid="app1-molecules-26-00137">Figure S4 and S5 (Supplementary file)</xref>.</p></sec><sec id="sec4dot5-molecules-26-00137"><title>4.5. DPPH (2,2-diphenyl-1-picrylhydrazyl) Free Radical Scavenging Assay</title><p>DPPH (2,2-diphenyl-1-picrylhydrazyl) free radicals scavenging potential of catechin was determined using Brand-Williams assay [<xref rid="B37-molecules-26-00137" ref-type="bibr">37</xref>] with some modification. DPPH solution was prepared in methanol (100 mL). 1 mg/mL catechin was also prepared in methanol with serial dilutions 31.05, 62.5, 250, 500, and 1000 &#x000b5;g/mL. Catechin (0.1 mL) was mixed with DPPH (3.0 mL) and incubated for 30 min at 23 &#x000b0;C. Finally absorbance was measured at 517 nm using UV spectrophotometer and ascorbic acid was used as a positive control. Results were taken in three replicates and represented as mean &#x000b1; SEM. Percent DPPH scavenging potential was calculated using the following Equation (1):<disp-formula id="FD1-molecules-26-00137"><label>(1)</label><mml:math id="mm1"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi>Free</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>radicals</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>scavenging</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>potential</mml:mi><mml:mtext>&#x000a0;</mml:mtext></mml:mrow><mml:mo>=</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:mfrac><mml:mrow><mml:mrow><mml:mtext>&#x000a0;</mml:mtext><mml:mi>Blank</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>sample</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi>sample</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>Blank</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>sample</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mo>.</mml:mo><mml:mtext>&#x000a0;</mml:mtext></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec4dot6-molecules-26-00137"><title>4.6. ABTS (2,2&#x02032;-azinobis-3-ethylbenzothiazoline-6-sulfonic acid) Free Radical Scavenging Assay</title><p>ABTS (2,2&#x02032;-azinobis-3-ethylbenzothiazoline-6-sulfonic acid) free radicals were produced according to the reported assay [<xref rid="B38-molecules-26-00137" ref-type="bibr">38</xref>]. Antiradical potential of catechin was measured by taking 300 &#x000b5;L catechin solution and 3.0 mL ABTS solution, mixed thoroughly and incubated for 6 min. Finally the absorbance was measured by UV spectrophotometer. Ascorbic acid as positive control as mentioned above have been used. Percent ABTS free radicals scavenging potential was calculated using Equation (1).</p></sec><sec id="sec4dot7-molecules-26-00137"><title>4.7. In Vitro &#x003b1;-Amylase Inhibitory Assay</title><p>The &#x003b1;-amylase inhibitory potential was estimated using 3,5-dinitrosalicylic acid (DNSA) assay [<xref rid="B39-molecules-26-00137" ref-type="bibr">39</xref>]. Isolated compound catechin was dissolved in mixture of DMSO (10%), Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> buffer (0.02M) and NaCl (0.006M) at pH 6.9 and then various dilutions were prepared in the range 31.05, 62.5, 125, 250, 500 and 1000 &#x003bc;g/mL. Enzyme &#x003b1;-amylase (200 &#x003bc;L; 2 units/mL) was mixed with catechin (200 &#x003bc;L) and incubated for 10 min at 30 &#x000b0;C. Then 200 &#x003bc;L starch (1%) solution was added to each serial dilution and incubated for 3 min. To stop the reaction 200 &#x003bc;L sodium potassium tartrate tetrahydrate (DNSA) reagent, 2M NaOH, and 20 mL of 3,5 dinitrosalicylic acid (96 mM) were added to the reaction mixture. The reaction mixtures were boiled at 85&#x02013;90 &#x000b0;C for 10 min in a water bath. After cooling the mixture was diluted with distilled water (5 mL) and then the absorbance was recorded at 540 nm through UV Visible spectrophotometer. A blank solution was prepared containing only isolated compound catechin but no enzyme. Standard acarbose (100 &#x003bc;g/mL&#x02013;2 &#x003bc;g/mL) was prepared as positive control. The &#x003b1;-amylase enzyme inhibitory activity was calculated using the Equation (2):<disp-formula id="FD2-molecules-26-00137"><label>(2)</label><mml:math id="mm2"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi>amylase</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>Inhibition</mml:mi><mml:mtext>&#x000a0;</mml:mtext></mml:mrow><mml:mo>=</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:mfrac><mml:mrow><mml:mrow><mml:mi>control</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi>sample</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>control</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec4dot8-molecules-26-00137"><title>4.8. In Vitro &#x003b1;-Glucosidase Inhibitory Assay</title><p>The &#x003b1;-glucosidase inhibition of isolated compound catechin was assessed according to the reported method [<xref rid="B40-molecules-26-00137" ref-type="bibr">40</xref>] with minor modifications. The reaction mixture was prepared by adding 100 &#x003bc;L &#x003b1;-glucosidase (0.5 unit/mL) enzyme, 600 &#x003bc;L phosphate buffer (0.1 M; pH 6.9), and 50 &#x003bc;L compound dilutions (31.05, 62.5, 125, 250, 500 and 1000 &#x000b5;g/mL). The reaction mixture was incubated at 37 &#x000b0;C for 15 min. The enzymatic reactions were started by adding 100 &#x003bc;L substrate (<italic>p</italic>-nitro-phenyl-&#x003b1;-<sc>d</sc>-glucopyranoside) solution (5 mM) prepared in phosphate buffer (0.1 M; pH 6.9), then incubated for 15 min at 37 &#x000b0;C. The reaction was stopped by adding 400 &#x003bc;L sodium carbonate (0.2 M) solution and finally absorbance was recorded at 405 nm. The reaction mixture without compound was used as a control and the blank solution was prepared without &#x003b1;-glucosidase enzyme. Percent &#x003b1;-glucosidase inhibitory potential was calculated by the following Equation (3):<disp-formula id="FD3-molecules-26-00137"><label>(3)</label><mml:math id="mm3"><mml:mrow><mml:mrow><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi>Glucosidase</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>Inhibition</mml:mi><mml:mtext>&#x000a0;</mml:mtext></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi>control</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi>sample</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>control</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>absorbance</mml:mi></mml:mrow></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec4dot9-molecules-26-00137"><title>4.9. Animals</title><p>The in vivo experiments were conducted on Sprague-Dawley adults albino rats having weight from 170&#x02013;200 g that were purchased from Rifah Institute of Pharmaceutical Sciences Islamabad, Pakistan. The animals were maintained at 22&#x02013;25 &#x000b0;C with food and fresh water ad libitum. The animals were acclimated to animal house conditions at room temperature around 22&#x02013;25 &#x000b0;C. The animals were housed three rats per cage with light and dark cycle of about 12 h. </p></sec><sec id="sec4dot10-molecules-26-00137"><title>4.10. Acute Toxicity Study</title><p>All the animals were divided into nine groups that were comprising of 8 animals each. The control group animals received tween-80 suspension, orally. All animals were then treated orally with different doses (50, 100, 150, 200, 250, 300, and 500 mg/kg body weight) of CTN for acute toxicity study. Immediately after dosing, the animals were observed continuously for 4 h for symptoms of toxicity (respiratory aches, motor activity, convulsions, muscle spasm, tremors, sedation, diarrhoea, lacrimation, hypnosis, salivation, and loss of righting reflex) in animals. All animals were kept under observation and seemed healthy at 24 h to 1 week with no obvious alterations in appearance or behavior. No mortality was observed up to one week. The CTN remained safe and nontoxic up to 500 mg/kg body weight dose range. Therefore, according to Organization for Economic Cooperation and Development (OECD) guidelines, CTN at dose 50 mg/kg body weight as 1/10th of the highest dose (500 mg/kg) for multiple dose investigation was selected to evaluate in vivo antidiabetic activity of CTN [<xref rid="B41-molecules-26-00137" ref-type="bibr">41</xref>].</p></sec><sec id="sec4dot11-molecules-26-00137"><title>4.11. Animal Experimental Design for Induction of Diabetes</title><p>Diabetes was induced according to the method previously described by Matsuzawa-Nagappa et al. [<xref rid="B42-molecules-26-00137" ref-type="bibr">42</xref>]. Animals were divided into two major groups. One group was given normal pellet diet and the other animal group was fed with high fat diet (HFD: 40% raw beef fat + 30% casein + 10% glucose + 7% wheat flour + 6% barn + 4% vitamin mixture and 3% salt mixture) for two weeks before commencing the experiment. After two weeks, induction of hyperglycemia was carried out in HFD Sprague-Dawley rats via a single intraperitoneal (i.p) injection of STZ (50 mg/kg) prepared in 0.9% normal saline solution after an overnight fast. Blood samples were collected from tail vein and through SD glucometer blood glucose level was measured after 72 h (of STZ injection). Rats with blood glucose levels higher than 300 mg/dL were considered as being diabetic. In the normal control groups only normal saline (8 mL/kg, p.o) was given as a vehicle. Isolated compound catechin was administered to the treatment groups from 3 days after STZ administration for 3 weeks. Blood glucose level and body weights were documented at weekly intervals.</p></sec><sec id="sec4dot12-molecules-26-00137"><title>4.12. Detailed Treatment Protocol</title><p>Rats were divided into 9 groups (<italic>n</italic> = 8) after an overnight fast for about 12 h. The first group labeled as normal control that takes normal saline orally while the rest of eight groups were considered HFD groups. In this study the STZ-induced diabetic model was used to evaluate the anti-hyperglycemic and anti-hyperlipidemic activity of isolated compound catechin (CTN) in chronic multiple dose experiment. The schematic treatment was as follows:</p><p>Group I: Normal control animals received normal saline (8 mL/kg, p.o)</p><p>Group II: Diabetic control received STZ (50 mg/kg, i.p.)+ Normal saline, p.o</p><p>Group III: Standard control group animals received STZ (50 mg/kg, i.p.) + glibenclamide (5 mg/kg, p.o)</p><p>Group IV: Treated group animals received STZ (50 mg/kg, i.p.) + CTN (2 mg/kg, p.o)</p><p>Group V: Treated group animals received STZ (50 mg/kg, i.p.) + CTN (5 mg/kg, p.o)</p><p>Group VI: Treated group animals received STZ (50 mg/kg, i.p.) + CTN (10 mg/kg, p.o)</p><p>Group VII: Treated group animals received STZ (50 mg/kg, i.p.) + CTN (15 mg/kg, p.o)</p><p>Group VIII: Treated group animals received STZ (50 mg/kg, i.p.) + CTN (30 mg/kg, p.o)</p><p>Group IX: Treated group animals received STZ (50 mg/kg, i.p.) + CTN (50 mg/kg, p.o)</p><p>All the animals were given their respective treatments for 21 days starts daily at 09:00 am. The fasting blood glucose levels were determined at 0, 4th, 7th, 10th, 15th and 21st days in fasting condition with the glucometer from the tail vein. The same protocol was repeated once again. Changes in the body weight of untreated control and experimental animals were documented in fasting condition at day 1 and after 21 days of experiment and are presented as % increase in body weight [<xref rid="B13-molecules-26-00137" ref-type="bibr">13</xref>].</p></sec><sec id="sec4dot13-molecules-26-00137"><title>4.13. Collection of Blood and Estimation of Biochemical Parameters</title><p>At the completion of in vivo antidiabetic activity on the 21st day, all animals were anesthetized by intraperitoneal (IP) injection of 35&#x02009;mg/kg pentobarbital sodium and euthanized by means of cervical decapitation according to the previously reported procedure illustrated in schedule-1 of UK, animal scientific procedure act; 1986. Blood collection was carried out through cardiac puncture, transferred to EDTA and non-EDTA containing tubes. Blood and sera were separated by centrifugation at 3500 rpm for 10 min for analysis of glucose and biochemical parameters such as serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), serum glutamate pyruvate transaminase (SGPT), and serum glutamate oxaloacetate transaminase (SGOT) [<xref rid="B41-molecules-26-00137" ref-type="bibr">41</xref>]. The concentration of lipid profile parameters; total cholesterol (TC), triglycerides (TG), low-density lipoproteins (LDL), high-density lipoprotein (HDL), and serum creatinine in serum were estimated using a biochemistry analyzer (PS-520; Shenzhen Procan Electronics, China) as per companies&#x02019; instructions using diagnostic kits (Reactivos, GPL Barcelona, Spain) [<xref rid="B41-molecules-26-00137" ref-type="bibr">41</xref>]. The level of glycosylated hemoglobin (HbA1c) was performed by an enzyme-linked immunosorbent assay (ELISA) kit according to the reported protocol [<xref rid="B7-molecules-26-00137" ref-type="bibr">7</xref>].</p></sec><sec id="sec4dot14-molecules-26-00137"><title>4.14. Measurement of Antioxidant Enzymes and Biochemical Parameters in Hepatic and Kidney Tissues</title><p>The liver and kidney tissue were removed, washed with cold saline solution and blotted dried. A weighed portion of liver and kidney portion were homogenized and 10 percent homogenate (<italic>w</italic>/<italic>v</italic>) was prepared in EDTA (1mM) and phosphate buffer (100mM) solution. Homogenates were placed at 4 &#x000b0;C for 20 min, and finally centrifuged at 3500 rpm for 15 min at 4 &#x000b0;C and supernatants were divided into aliquots and stored at &#x02212;20 &#x000b0;C until assessed for different enzymes. According to the reported method [<xref rid="B43-molecules-26-00137" ref-type="bibr">43</xref>] activities of glutathione peroxidase (GPx) and total content of reduced glutathione (GSH) level in the supernatant obtained from liver and kidney tissues were analyzed. Thiobarbituric acid reactive substance (TBARS) assay was used for estimation of and malondialdehyde (MDA) level (lipid peroxidation) [<xref rid="B6-molecules-26-00137" ref-type="bibr">6</xref>].</p></sec><sec id="sec4dot15-molecules-26-00137"><title>4.15. Histopathology</title><p>For histopathological examination the pancreas portion were immediately removed, washed thoroughly with saline solution to remove the blood. Finally the pancreas tissue were fixed in 10% formalin, dehydrated with ethanol-xylene mixtures and fixed with paraffin. Tissue blocks were sectioned with about 4.5&#x02013;6.5 &#x003bc;m thickness through Microtome (ACCU-Cut<sup>&#x000ae;</sup> SRM<sup>&#x02122;</sup>: 200 Sakura). Slides were stained with Hematoxylin and Eosin (H and E) dye by means of automatic slide stainer (Sakura Tissue-Tek<sup>&#x000ae;</sup> DRS<sup>&#x02122;</sup> 2000; Salt Lake Utah, USA). The stained slides were cleaned properly and observed under microscope to see alteration in pancreatic tissues (architecture of STZ-induced diabetic group) and treated (glibenclamide/extract) groups. The samples were processed according to reported protocols [<xref rid="B43-molecules-26-00137" ref-type="bibr">43</xref>].</p></sec><sec id="sec4dot16-molecules-26-00137"><title>4.16. Statistical Analysis</title><p>All in vitro and in vivo experiments were performed in three replicates. All results were determined as mean &#x000b1; SEM. The Student&#x02019;s <italic>t</italic>-test and one way ANOVA followed by Dunnett&#x02019;s post hoc multiple comparison test was used. <italic>p</italic> &#x02264; 0.05 were considered as significant. Linear regression was used to calculate IC<sub>50</sub> for % DPPH, ABTS, &#x003b1;-amylase, and &#x003b1;-glucosidase inhibition against the different concentration of test samples by means of Excel program 2007.</p></sec></sec><sec sec-type="conclusions" id="sec5-molecules-26-00137"><title>5. Conclusions</title><p>The observed post-prandial hypoglycemic potential of <italic>E. umbellata</italic> catechin can be attributed to its inhibitor effects on carbohydrate digestive enzymes (&#x003b1;-amylase and &#x003b1;-glucosidase). CTN played a significant role in the amelioration of oxidative stress and diabetic complications in STZ-induced injuries in liver and kidneys in rats. CTN significantly decreased hepatic, renal, and lipid parameters, and HbA1c levels in diabetic rats while significantly increased the HDL level, antioxidant enzyme GPx and reduced GSH content. It can be concluded from the results of this study that <italic>E. umbellata</italic> berries catechin could effectively be used as an antioxidant and anti-hyperglycemic factor that has potential to reduce the MDA level in STZ-induced diabetic rats, and thus might be a useful candidate to be used in the management of type-2 diabetes.</p></sec></body><back><ack><title>Acknowledgments</title><p>Authors wish to thanks Research Supporting Project at King Saud University via grant number RSP/2020/45 and article processing charge (APC) was also supported by the Research Supporting Project (RSP/2020/45). </p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-molecules-26-00137"><title>Supplementary Materials</title><p>The following are available online, Figure S1: Structural formula of catechin, Figure S2: <sup>1</sup>H-NMR (METHANOL-d<sub>4</sub>, 300 MHz) of isolated compound catechin, Figure S3: <sup>13</sup>C-NMR (METHANOL-d<sub>4</sub>, 75MHz of isolated compound catechin, Figure S4: EIMS of isolated compound catechin, Figure S5: FTIR spectra of isolated compound catechin, Table S1: % DPPH and ABTS free radical scavenging activity of catechin isolated from <italic>Elaeagnus umbellata</italic> fruit at various concentrations and Table S2: % &#x003b1;-amylase and &#x003b1;-glucosidase inhibition potential of catechin isolated from of <italic>Elaeagnus umbellata</italic> fruit at various concentrations.</p><supplementary-material content-type="local-data" id="molecules-26-00137-s001"><media xlink:href="molecules-26-00137-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>N.N. carried out plants collection, extraction, and isolation, in vitro and in vivo experimental work, literature search, and wrote the manuscript; M.Z. supervised the work, finalized the manuscript for publication and revised the paper; R.U. carried out the formal analysis; E.E. and G.A.E.M. has done final editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>Research Supporting Project at King Saud University via grant number RSP/2020/45.</p></notes><notes><title>Institutional Review Board Statement</title><p>All procedures related to animal were carried out according to the ARRIVE guidelines and approved from the Departmental Animal Ethical Committee (DAEC/PHARM/2018/1), University of Malakand, Pakistan. These guidelines were in accordance with the internationally documented principles for laboratory used and care.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this manuscript belong to the PhD research work of Mrs. Nausheen Nazir and has not been deposited in any repository yet. However, the data are available to the researchers upon request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflict of interests.</p></notes><notes><title>Sample Availability</title><p>Not available.</p></notes><glossary><title>Abbrevations</title><p>Me-Ext; Hydromethanolic extract, Hex.Ext; <italic>n</italic>-hexane extract fraction, Chf-Ext; Chloroform extract fraction, EtAc-Ext; Ethyl acetate extract fraction, But.Ext; <italic>n</italic>-Butanol extract fraction, Aq.Ext; Aqueous extract fraction, CTN; catechin, DPPH; 2,2-diphenyl-1-picrylhydrazyl, ABTS; 2,2&#x02032;-azinobis-3-ethylbenzothiazoline-6-sulfonic acid, Rt; retention time, SEM; Standard error mean, ROS; Reactive oxygen species, DM; Diabetes mellitus, AD; Alzheimer&#x02019;s Disease, T2D; Type 2 diabetes, UVAD; ultraviolet array detector, HFD; high-fat diet, STZ; Streptozotocin, DNSA; 3,5-dinitrosalicylic acid, TC; Total cholesterol, TG; Triglycerides, LDL; Low density lipoproteins, HDL; High density lipoprotein, SGPT; serum glutamate pyruvate transaminase, SGOT; serum glutamate oxaloacetate transaminase, ALP; serum alkaline phosphatase, AST; aspartate aminotransferase, Hb1c; glycosylated haemoglobin, MDA; Malondialdehyde, GSH; Glutathione, GPx; Glutathione peroxidase, TBRA; Thiobarbituric acid, FTIR; Fourier Transform Infrared-spectroscopy, i.p.; Intraperitoneal, IC<sub>50</sub>; Minimum inhibitory concentration, ANOVA; Analysis Of Variance, NMR; Nuclear-magnetic-resonance, p.o.; Per oral, C13NMR; Carbon-13 Nuclear Magnetic-resonance, EI-MS; Electron Ionization Mass Spectrometry.</p></glossary><ref-list><title>References</title><ref id="B1-molecules-26-00137"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>A.</given-names></name><name><surname>Tanko</surname><given-names>Y.</given-names></name><name><surname>Okasha</surname><given-names>M.A.</given-names></name><name><surname>Magaji</surname><given-names>R.A.</given-names></name><name><surname>Yaro</surname><given-names>A.H.</given-names></name></person-group><article-title>Effects of aqueous leaves extract of Ocimum gratissimum on blood glucose levels of streptozotocin-induced diabetic Wistar rats</article-title><source>Afr. J. Biotechnol.</source><year>2007</year><volume>16</volume><fpage>2087</fpage><lpage>2090</lpage></element-citation></ref><ref id="B2-molecules-26-00137"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>L.W.</given-names></name></person-group><article-title>Traditional medicinal plants of Manipur as anti-diabetics</article-title><source>J. Med. Plant. Res.</source><year>2011</year><volume>5</volume><fpage>677</fpage><lpage>687</lpage></element-citation></ref><ref id="B3-molecules-26-00137"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandran</surname><given-names>R.</given-names></name><name><surname>Parimelazhagan</surname><given-names>T.</given-names></name><name><surname>Shanmugam</surname><given-names>S.</given-names></name><name><surname>Thankarajan</surname><given-names>S.</given-names></name></person-group><article-title>Antidiabetic activity of Syzygium calophyllifoliumin Streptozotocin-Nicotinamide induced Type-2 diabetic rats</article-title><source>Biomed. Pharmacother.</source><year>2016</year><volume>82</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.05.036</pub-id><?supplied-pmid 27470395?><pub-id pub-id-type="pmid">27470395</pub-id></element-citation></ref><ref id="B4-molecules-26-00137"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scaroni</surname><given-names>C.</given-names></name><name><surname>Zilio</surname><given-names>M.</given-names></name><name><surname>Foti</surname><given-names>M.</given-names></name><name><surname>Boscaro</surname><given-names>M.</given-names></name></person-group><article-title>Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management</article-title><source>Endocr. Rev.</source><year>2017</year><volume>38</volume><fpage>189</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1210/er.2016-1105</pub-id><?supplied-pmid 28368467?><pub-id pub-id-type="pmid">28368467</pub-id></element-citation></ref><ref id="B5-molecules-26-00137"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulton</surname><given-names>A.J.</given-names></name><name><surname>Vileikyte</surname><given-names>L.</given-names></name><name><surname>Ragnarson-Tennvall</surname><given-names>G.</given-names></name><name><surname>Apelqvist</surname><given-names>J.</given-names></name></person-group><article-title>The global burden of diabetic foot disease</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1719</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67698-2</pub-id><pub-id pub-id-type="pmid">16291066</pub-id></element-citation></ref><ref id="B6-molecules-26-00137"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>F.</given-names></name><name><surname>Sono</surname><given-names>Y.</given-names></name><name><surname>Ito</surname><given-names>T.</given-names></name></person-group><article-title>Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation</article-title><source>Antioxidants (Basel)</source><year>2019</year><volume>8</volume><elocation-id>72</elocation-id><pub-id pub-id-type="doi">10.3390/antiox8030072</pub-id></element-citation></ref><ref id="B7-molecules-26-00137"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillay</surname><given-names>S.</given-names></name></person-group><article-title>Pilot study involving the use of point-of-care glycated haemoglobin (HbA1c) testing for screening and monitoring of diabetes mellitus in the public healthcare sector in KwaZulu-Natal</article-title><source>J. Endocrinol. Metabol. Diabetes S. Afr.</source><year>2020</year><volume>25</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1080/16089677.2020.1793488</pub-id></element-citation></ref><ref id="B8-molecules-26-00137"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>W.Y.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Heng</surname><given-names>D.</given-names></name><name><surname>Tai</surname><given-names>S.E.</given-names></name><name><surname>Khoo</surname><given-names>C.M.</given-names></name><name><surname>Loh</surname><given-names>P.T.</given-names></name></person-group><article-title>Screening for diabetes with HbA1c: Test performance of HbA1c compared to fasting plasma glucose among Chinese, Malay and Indian community residents in Singapore</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>12419</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-29998-z</pub-id><pub-id pub-id-type="pmid">30127499</pub-id></element-citation></ref><ref id="B9-molecules-26-00137"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadkar</surname><given-names>K.A.</given-names></name><name><surname>Magdum</surname><given-names>C.S.</given-names></name><name><surname>Patil</surname><given-names>S.S.</given-names></name><name><surname>Naikwade</surname><given-names>N.S.</given-names></name></person-group><article-title>Antidiabetic potential and Indian medicinal plants</article-title><source>J. Herb. Med. Toxicol.</source><year>2008</year><volume>2</volume><fpage>45</fpage><lpage>50</lpage></element-citation></ref><ref id="B10-molecules-26-00137"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Hori</surname><given-names>A.</given-names></name><name><surname>Nishiura</surname><given-names>C.</given-names></name><name><surname>Sasaki</surname><given-names>N.</given-names></name><name><surname>Okazaki</surname><given-names>H.</given-names></name><name><surname>Nakagawa</surname><given-names>T.</given-names></name><name><surname>Honda</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>S.</given-names></name><name><surname>Tomita</surname><given-names>K.</given-names></name><name><surname>Miyamoto</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Japan Epidemiology Collaboration on Occupational Health Study Group. Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study</article-title><source>PLoS ONE</source><year>2016</year><volume>20</volume><fpage>e0159071</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0159071</pub-id></element-citation></ref><ref id="B11-molecules-26-00137"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olas</surname><given-names>B.</given-names></name></person-group><article-title>Berry Phenolic Antioxidants-Implications for Human Health?</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00078</pub-id><?supplied-pmid 29662448?><pub-id pub-id-type="pmid">29662448</pub-id></element-citation></ref><ref id="B12-molecules-26-00137"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>T.</given-names></name><name><surname>Singh</surname><given-names>P.A.</given-names></name><name><surname>Vorsa</surname><given-names>N.</given-names></name></person-group><article-title>Human Glycemic Response and Phenolic Content of Unsweetened Cranberry Juice</article-title><source>J. Med. Food</source><year>2008</year><volume>11</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1089/jmf.2007.531</pub-id><?supplied-pmid 18361737?><pub-id pub-id-type="pmid">18361737</pub-id></element-citation></ref><ref id="B13-molecules-26-00137"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazir</surname><given-names>N.</given-names></name><name><surname>Zahoor</surname><given-names>M.</given-names></name><name><surname>Nisar</surname><given-names>M.</given-names></name><name><surname>Khan</surname><given-names>I.</given-names></name><name><surname>Karim</surname><given-names>N.</given-names></name><name><surname>Abdel-Halim</surname><given-names>H.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name></person-group><article-title>Phytochemical analysis and antidiabetic potential of Elaeagnus umbellata (Thunb.) in streptozotocin-induced diabetic rats: Pharmacological and computational approach</article-title><source>BMC Complement. Altern. Med.</source><year>2018</year><volume>18</volume><fpage>332</fpage><pub-id pub-id-type="doi">10.1186/s12906-018-2381-8</pub-id><pub-id pub-id-type="pmid">30545352</pub-id></element-citation></ref><ref id="B14-molecules-26-00137"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>S.D.</given-names></name><name><surname>Sabir</surname><given-names>M.S.</given-names></name><name><surname>Juma</surname><given-names>M.</given-names></name><name><surname>Asad</surname><given-names>H.S.</given-names></name></person-group><article-title>Morphological and biochemical variations in Elaeagnus umbellata Thunb. from mountains of Pakistan</article-title><source>Acta Bot. Croat.</source><year>2005</year><volume>64</volume><fpage>121</fpage><lpage>128</lpage></element-citation></ref><ref id="B15-molecules-26-00137"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazir</surname><given-names>N.</given-names></name><name><surname>Zahoor</surname><given-names>M.</given-names></name><name><surname>Nisar</surname><given-names>M.</given-names></name></person-group><article-title>A Review on Traditional Uses and Pharmacological Importance of Genus Elaeagnus Species</article-title><source>Bot. Rev.</source><year>2020</year><volume>86</volume><fpage>247</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1007/s12229-020-09226-y</pub-id></element-citation></ref><ref id="B16-molecules-26-00137"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruisong</surname><given-names>P.</given-names></name><name><surname>Mo</surname><given-names>Y.</given-names></name><name><surname>Richard</surname><given-names>B.</given-names></name><name><surname>Bradley</surname><given-names>W.</given-names></name></person-group><article-title>Phenolic and tocopherol content of autumn olive (Elaeagnus umbellate) berries</article-title><source>J. Funct. Foods</source><year>2015</year><volume>16</volume><fpage>305</fpage><lpage>314</lpage></element-citation></ref><ref id="B17-molecules-26-00137"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazir</surname><given-names>N.</given-names></name><name><surname>Zahoor</surname><given-names>M.</given-names></name><name><surname>Nisar</surname><given-names>M.</given-names></name><name><surname>Karim</surname><given-names>N.</given-names></name><name><surname>Latif</surname><given-names>A.</given-names></name><name><surname>Ahmad</surname><given-names>S.</given-names></name><name><surname>Uddin</surname><given-names>Z.</given-names></name></person-group><article-title>Evaluation of neuroprotective and anti-amnesic effects of Elaeagnus umbellata Thunb. On scopolamine-induced memory impairment in mice</article-title><source>BMC Complement. Med. Ther.</source><year>2020</year><volume>20</volume><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/s12906-020-02942-3</pub-id><pub-id pub-id-type="pmid">32397979</pub-id></element-citation></ref><ref id="B18-molecules-26-00137"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penelope</surname><given-names>P.V.</given-names></name><name><surname>Brent</surname><given-names>B.</given-names></name><name><surname>Ingrid</surname><given-names>F.</given-names></name><name><surname>Luke</surname><given-names>H.</given-names></name></person-group><article-title>Lycopene and total phenol content of Autum Olive (Elaegnus umbellata) selections</article-title><source>HortScience</source><year>2005</year><volume>40</volume><fpage>883</fpage><lpage>884</lpage></element-citation></ref><ref id="B19-molecules-26-00137"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>N.</given-names></name><name><surname>Shin</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>Y.S.</given-names></name><name><surname>Kim</surname><given-names>J.U.</given-names></name></person-group><article-title>Activity of catechins and their applications</article-title><source>biomed. dermatol.</source><year>2020</year><volume>4</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s41702-020-0057-8</pub-id></element-citation></ref><ref id="B20-molecules-26-00137"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>Q.F.</given-names></name><name><surname>Liu</surname><given-names>H.Y.</given-names></name><name><surname>Pi</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Quon</surname><given-names>M.J.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name></person-group><article-title>Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5&#x02019;-AMP-activated protein kinase</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>30143</fpage><lpage>30149</lpage><pub-id pub-id-type="doi">10.1074/jbc.M702390200</pub-id><pub-id pub-id-type="pmid">17724029</pub-id></element-citation></ref><ref id="B21-molecules-26-00137"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Sheng</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>(+)-Catechin ameliorates diabetic nephropathy by trapping methylglyoxal in type 2 diabetic mice</article-title><source>Mol. Nutr. Food Res.</source><year>2014</year><volume>58</volume><fpage>2249</fpage><lpage>2260</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201400533</pub-id><?supplied-pmid 25243815?><pub-id pub-id-type="pmid">25243815</pub-id></element-citation></ref><ref id="B22-molecules-26-00137"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ert&#x000fc;rk&#x000fc;ner</surname><given-names>S.P.</given-names></name><name><surname>Ba&#x0015f;ar</surname><given-names>M.</given-names></name><name><surname>Tun&#x000e7;demir</surname><given-names>M.</given-names></name><name><surname>Se&#x000e7;kin</surname><given-names>&#x00130;.</given-names></name></person-group><article-title>The comparative effects of perindopril and catechin on mesangial matrix and podocytes in the streptozotocin induced diabetic rats</article-title><source>Pharmacol. Rep.</source><year>2014</year><volume>66</volume><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.pharep.2013.09.010</pub-id><?supplied-pmid 24911082?><pub-id pub-id-type="pmid">24911082</pub-id></element-citation></ref><ref id="B23-molecules-26-00137"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laoufi</surname><given-names>H.</given-names></name><name><surname>Nabila</surname><given-names>B.</given-names></name><name><surname>Adjdir</surname><given-names>S.</given-names></name><name><surname>Rabah</surname><given-names>D.</given-names></name></person-group><article-title>In vitro &#x003b1;-amylase and &#x003b1;-glucosidase inhibitory activity of Ononis angustissima extracts</article-title><source>J. Appl. Pharm. Sci.</source><year>2017</year><volume>7</volume><fpage>191</fpage><lpage>198</lpage></element-citation></ref><ref id="B24-molecules-26-00137"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chelladurai</surname><given-names>G.R.M.</given-names></name><name><surname>Chinnachamy</surname><given-names>C.</given-names></name></person-group><article-title>Alpha amylase and Alpha glucosidase inhibitory effects of aqueous stem extract of Salacia oblonga and its GC-MS analysis</article-title><source>Braz. J. Pharm. Sci.</source><year>2018</year><volume>54</volume><fpage>e17151</fpage><pub-id pub-id-type="doi">10.1590/s2175-97902018000117151</pub-id></element-citation></ref><ref id="B25-molecules-26-00137"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>F.</given-names></name><name><surname>Saqib</surname><given-names>Q.N.</given-names></name><name><surname>Ashraf</surname><given-names>M.</given-names></name></person-group><article-title>Zanthoxylum armatum DC extracts from fruit, bark and leaf induce hypolipidemic and hypoglycemic effects in mice- in vivo and in vitro study</article-title><source>BMC Complement. Altern. Med.</source><year>2018</year><volume>18</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-018-2138-4</pub-id><pub-id pub-id-type="pmid">29463309</pub-id></element-citation></ref><ref id="B26-molecules-26-00137"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Azain</surname><given-names>M.</given-names></name><name><surname>Crowe-White</surname><given-names>K.</given-names></name><name><surname>Mumaw</surname><given-names>J.</given-names></name><name><surname>Grimes</surname><given-names>J.A.</given-names></name><name><surname>Schmiedt</surname><given-names>C.</given-names></name><name><surname>Barletta</surname><given-names>M.</given-names></name><name><surname>Rayalam</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>H.J.</given-names></name></person-group><article-title>Effect of Acute Ingestion of Green Tea Extract and Lemon Juice on Oxidative Stress and Lipid Profile in Pigs Fed a High-Fat Diet</article-title><source>Antioxidants</source><year>2019</year><volume>8</volume><elocation-id>195</elocation-id><pub-id pub-id-type="doi">10.3390/antiox8060195</pub-id></element-citation></ref><ref id="B27-molecules-26-00137"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashid</surname><given-names>U.</given-names></name><name><surname>Khan</surname><given-names>M.R.</given-names></name><name><surname>Sajid</surname><given-names>M.</given-names></name></person-group><article-title>Antioxidant, anti-inflammatory and hypoglycemic effects of Fagonia olivieri DC on STZ-nicotinamide induced diabetic rats-In vivo and in vitro study</article-title><source>J. Ethnopharmacol</source><year>2019</year><volume>242</volume><fpage>112038</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2019.112038</pub-id><pub-id pub-id-type="pmid">31247238</pub-id></element-citation></ref><ref id="B28-molecules-26-00137"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Prasad</surname><given-names>S.K.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Banerjee</surname><given-names>O.</given-names></name><name><surname>Seal</surname><given-names>T.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name><name><surname>Maji</surname><given-names>B.K.</given-names></name></person-group><article-title>Protective efficacy of Tinospora sinensis against streptozotocin induced pancreatic islet cell injuries of diabetic rats and its correlation to its phytochemical profiles</article-title><source>J. Ethnopharmacol.</source><year>2020</year><volume>248</volume><fpage>112356</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2019.112356</pub-id><pub-id pub-id-type="pmid">31669668</pub-id></element-citation></ref><ref id="B29-molecules-26-00137"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koech</surname><given-names>J.K.</given-names></name><name><surname>Nandwa</surname><given-names>A.N.</given-names></name><name><surname>Macharia</surname><given-names>B.N.</given-names></name><name><surname>Keter</surname><given-names>L.K.</given-names></name><name><surname>Mwikwabe</surname><given-names>N.M.</given-names></name><name><surname>Tuei</surname><given-names>V.C.</given-names></name></person-group><article-title>Hypoglycemic, hypolipidemic, and hepatoprotective effects of Polyscias fulva (Hiern) Harms ethanolic bark extract in streptozotocin-induced diabetic Wistar rats</article-title><source>Int. J. Diabetes Dev. Ctries.</source><year>2020</year><volume>40</volume><fpage>570</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1007/s13410-020-00818-3</pub-id></element-citation></ref><ref id="B30-molecules-26-00137"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verg&#x000e8;s</surname><given-names>B.</given-names></name></person-group><article-title>Pathophysiology of diabetic dyslipidaemia: Where are we?</article-title><source>Diabetologia</source><year>2015</year><volume>58</volume><fpage>886</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1007/s00125-015-3525-8</pub-id><pub-id pub-id-type="pmid">25725623</pub-id></element-citation></ref><ref id="B31-molecules-26-00137"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabu</surname><given-names>M.C.</given-names></name><name><surname>Smitha</surname><given-names>K.</given-names></name><name><surname>Kuttan</surname><given-names>R.</given-names></name></person-group><article-title>Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes</article-title><source>J. Ethnopharmacol.</source><year>2002</year><volume>83</volume><fpage>109</fpage><lpage>116</lpage><?supplied-pmid 12413715?><pub-id pub-id-type="pmid">12413715</pub-id></element-citation></ref><ref id="B32-molecules-26-00137"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krha&#x0010d;</surname><given-names>M.</given-names></name><name><surname>Lovren&#x0010d;i&#x00107;</surname><given-names>M.V.</given-names></name></person-group><article-title>Update on biomarkers of glycemic control</article-title><source>World J. Diabetes</source><year>2019</year><volume>10</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.4239/wjd.v10.i1.1</pub-id><?supplied-pmid 30697366?><pub-id pub-id-type="pmid">30697366</pub-id></element-citation></ref><ref id="B33-molecules-26-00137"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>D.</given-names></name><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Antihyperglycemic effect of Ginkgo biloba extract in streptozotocin-induced diabetes in rats</article-title><source>Biomed. Res. Int.</source><year>2013</year><volume>2013</volume><fpage>162724</fpage><pub-id pub-id-type="doi">10.1155/2013/162724</pub-id><?supplied-pmid 23509685?><pub-id pub-id-type="pmid">23509685</pub-id></element-citation></ref><ref id="B34-molecules-26-00137"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyedemi</surname><given-names>S.O.</given-names></name><name><surname>Adewusi</surname><given-names>E.A.</given-names></name><name><surname>Aiyegoro</surname><given-names>O.A.</given-names></name><name><surname>Akinpelu</surname><given-names>D.A.</given-names></name></person-group><article-title>Antidiabetic and haematological effect of aqueous extract of stem bark of Afzelia africana (Smith) on streptozotocin-induced diabetic Wistar rats</article-title><source>Asian Pac. J. Trop. Biomed.</source><year>2011</year><volume>1</volume><fpage>353</fpage><lpage>358</lpage><?supplied-pmid 23569792?><pub-id pub-id-type="pmid">23569792</pub-id></element-citation></ref><ref id="B35-molecules-26-00137"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramadan</surname><given-names>B.K.</given-names></name><name><surname>Schaalan</surname><given-names>M.F.</given-names></name><name><surname>Tolba</surname><given-names>A.M.</given-names></name></person-group><article-title>Hypoglycemic and pancreatic protective effects of Portulaca oleracea extract in alloxan induced diabetic rats</article-title><source>BMC Complement. Altern. Med.</source><year>2017</year><volume>17</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-016-1530-1</pub-id><pub-id pub-id-type="pmid">28077129</pub-id></element-citation></ref><ref id="B36-molecules-26-00137"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arzani Birgani</surname><given-names>G.</given-names></name><name><surname>Ahangarpour</surname><given-names>A.</given-names></name><name><surname>Khorsandi</surname><given-names>L.</given-names></name><name><surname>Fathi Moghaddam</surname><given-names>H.</given-names></name></person-group><article-title>Anti-diabetic effect of betulinic acid on streptozotocin-nicotinamide induced diabetic male mouse model</article-title><source>Braz. J. Pharm. Sci.</source><year>2018</year><volume>54</volume><pub-id pub-id-type="doi">10.1590/s2175-97902018000217171</pub-id></element-citation></ref><ref id="B37-molecules-26-00137"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand-Williams</surname><given-names>W.</given-names></name><name><surname>Cuvelier</surname><given-names>M.</given-names></name><name><surname>Berset</surname><given-names>C.</given-names></name></person-group><article-title>Use of a free radical method to evaluate antioxidant activity</article-title><source>LWT-Food Sci. Technol.</source><year>1995</year><volume>28</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0023-6438(95)80008-5</pub-id></element-citation></ref><ref id="B38-molecules-26-00137"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Re</surname><given-names>R.</given-names></name><name><surname>Pellegrini</surname><given-names>N.</given-names></name><name><surname>Proteggente</surname><given-names>A.</given-names></name><name><surname>Pannala</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Rice-Evans</surname><given-names>C.</given-names></name></person-group><article-title>Antioxidant activity applying an improved ABTS radical cation decolorization assay</article-title><source>Free Radic. Biol. Med.</source><year>1999</year><volume>26</volume><fpage>1231</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1016/S0891-5849(98)00315-3</pub-id><pub-id pub-id-type="pmid">10381194</pub-id></element-citation></ref><ref id="B39-molecules-26-00137"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranilla</surname><given-names>L.G.</given-names></name><name><surname>Kwon</surname><given-names>Y.I.</given-names></name><name><surname>Apostolidis</surname><given-names>E.</given-names></name><name><surname>Shetty</surname><given-names>K.</given-names></name></person-group><article-title>Phenolic compounds, antioxidant activity and in vitro inhibitory potential against key enzymes relevant for hyperglycemia and hypertension of commonly used medicinal plants, herbs and species in Latin America</article-title><source>Bioresour. Technol.</source><year>2010</year><volume>101</volume><fpage>4676</fpage><lpage>4689</lpage><pub-id pub-id-type="doi">10.1016/j.biortech.2010.01.093</pub-id><pub-id pub-id-type="pmid">20185303</pub-id></element-citation></ref><ref id="B40-molecules-26-00137"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>B.</given-names></name><name><surname>Salunke</surname><given-names>R.</given-names></name><name><surname>Balomajumder</surname><given-names>C.</given-names></name><name><surname>Daniel</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>P.</given-names></name></person-group><article-title>Anti-diabetic potential of alkaloid rich fraction from Capparis decidua on diabetic mice</article-title><source>J. Ethnopharmacol</source><year>2010</year><volume>127</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2009.10.013</pub-id><pub-id pub-id-type="pmid">19837152</pub-id></element-citation></ref><ref id="B41-molecules-26-00137"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa-Nagata</surname><given-names>N.</given-names></name><name><surname>Takamura</surname><given-names>T.</given-names></name><name><surname>Ando</surname><given-names>H.</given-names></name><name><surname>Nakamura</surname><given-names>S.</given-names></name><name><surname>Kurita</surname><given-names>S.</given-names></name><name><surname>Misu</surname><given-names>H.</given-names></name><name><surname>Ota</surname><given-names>T.</given-names></name><name><surname>Yokoyama</surname><given-names>M.</given-names></name><name><surname>Honda</surname><given-names>M.</given-names></name><name><surname>Miyamoto</surname><given-names>K.I.</given-names></name><etal/></person-group><article-title>Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity</article-title><source>Metabolism</source><year>2008</year><volume>57</volume><fpage>1071</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2008.03.010</pub-id><?supplied-pmid 18640384?><pub-id pub-id-type="pmid">18640384</pub-id></element-citation></ref><ref id="B42-molecules-26-00137"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagappa</surname><given-names>A.N.</given-names></name><name><surname>Thakurdesai</surname><given-names>P.A.</given-names></name><name><surname>VenkatRao</surname><given-names>N.</given-names></name><name><surname>Singh</surname><given-names>J.</given-names></name></person-group><article-title>Antidiabetic activity of Terminaliacatappa Linn fruits</article-title><source>J. Ethnopharmacol</source><year>2003</year><volume>88</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S0378-8741(03)00208-3</pub-id><pub-id pub-id-type="pmid">12902049</pub-id></element-citation></ref><ref id="B43-molecules-26-00137"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>J.</given-names></name><name><surname>Akhtar</surname><given-names>N.</given-names></name><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Ahmad</surname><given-names>K.</given-names></name><name><surname>Ahmad</surname><given-names>M.</given-names></name><name><surname>Sultana</surname><given-names>S.</given-names></name><name><surname>Asif</surname><given-names>H.M.</given-names></name></person-group><article-title>Phytochemical Screening and Hepatoprotective Effect of Alhagi maurorum Boiss (Leguminosae) Against Paracetamol-Induced Hepatotoxicity in Rabbits</article-title><source>Trop. J. Pharm. Res.</source><year>2015</year><volume>14</volume><fpage>1029</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.4314/tjpr.v14i6.13</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="molecules-26-00137-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Percent in vitro free radicals (DPPH and ABTS) scavenging and antidiabetic (&#x003b1;-amylase and &#x003b1;-glucosidase) activity of <italic>E. umbellata</italic> berries catechin. (<bold>A</bold>) % DPPH scavenging activity, (<bold>B</bold>) % ABTS scavenging activity, (<bold>C</bold>) percent &#x003b1;-amylase inhibition potential, (<bold>D</bold>) &#x003b1;-glucosidase inhibition potential of <italic>E. umbellata</italic> berries catechin at various concentrations.</p></caption><graphic xlink:href="molecules-26-00137-g001a"/><graphic xlink:href="molecules-26-00137-g001b"/></fig><fig id="molecules-26-00137-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Effect of various treatments on blood glucose level and body weight of STZ-induced diabetic rats (<bold>A</bold>,<bold>B</bold>). Blood glucose level in different treatment groups (<bold>C</bold>,<bold>D</bold>). Effect of various treatment groups on body weight in STZ-induced diabetic rats. (<bold>A</bold>) is showing the blood glucose levels at the end of treatment period while (<bold>B</bold>) shows blood glucose levels at different week. (<bold>C</bold>) is showing the body weight (mg/kg) at the end of treatment period while (<bold>D</bold>) shows body weight (mg/kg) at different week. [The values are expressed as mean &#x000b1; SEM. ns = non-significant. Each value corresponds to a mean of eight animals. <bold><sup>###</sup></bold>
<italic>p</italic> &#x002c2; 0.001; comparison of <sup>a</sup>(normal control) vs. <sup>b</sup>(diabetic control) using Student&#x02019;s <italic>t</italic>-test, * <italic>p</italic> &#x002c2; 0.05, ** <italic>p</italic> &#x002c2; 0.01, *** <italic>p</italic> &#x0003c; 0.001; comparison of <sup>b</sup>(diabetic control) vs.<sup>c</sup> (glibenclamide and CTN treated groups) using one way ANOVA followed by Dunnett&#x02019;s post hoc multiple comparison test].</p></caption><graphic xlink:href="molecules-26-00137-g002"/></fig><fig id="molecules-26-00137-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Effects of catechin on the level of liver serum biochemical parameters in STZ-induced diabetic rats: (<bold>A</bold>) Serum level of ALP, (<bold>B</bold>) serum level of AST, (<bold>C</bold>) serum level of SGPT, (<bold>D</bold>) serum level of SGOT, (<bold>E</bold>) serum level of creatinine in STZ-induced diabetic rats. The values are expressed as mean &#x000b1; SEM. Each value corresponds to a mean of eight animals <sup>###</sup>
<italic>p</italic> &#x0003c; 0.001; comparison of <sup>a</sup>(normal control) vs. <sup>b</sup>(diabetic control) using Student&#x02019;s <italic>t</italic>-test, ** <italic>p</italic> &#x002c2; 0.01, *** <italic>p</italic> &#x0003c; 0.001; comparison of <sup>b</sup>(diabetic control) vs. <sup>c</sup>(Glibenclamide and CTN treated groups) using one way ANOVA followed by Dunnett&#x02019;s post hoc multiple comparison test.</p></caption><graphic xlink:href="molecules-26-00137-g003"/></fig><fig id="molecules-26-00137-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Effects of catechin on the level of serum lipid parameters and Hb1c level in STZ-induced diabetic rats (<bold>A</bold>) Serum level of TC, (<bold>B</bold>) serum level of TG, (<bold>C</bold>) serum level of LDL, (<bold>D</bold>) serum level of HDL, (<bold>E</bold>) serum level of Hb1c in STZ-induced diabetic rats. The values are expressed as mean &#x000b1; SEM. Each value corresponds to a mean of eight animals ### <italic>p</italic> &#x002c2; 0.001; comparison of <sup>a</sup>(normal control) vs. <sup>b</sup>(diabetic control) using Student&#x02019;s <italic>t</italic>-test, * <italic>p</italic> &#x002c2; 0.05, ** <italic>p</italic> &#x002c2; 0.01, *** <italic>p</italic> &#x0003c; 0.001; comparison of <sup>b</sup>(diabetic control) vs. <sup>c</sup>(glibenclamide and CTN treated groups) using one way ANOVA followed by Dunnett&#x02019;s post hoc multiple comparison test.</p></caption><graphic xlink:href="molecules-26-00137-g004"/></fig><fig id="molecules-26-00137-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Effects of catechin (2, 5, 10, 15, 30, and 50 mg/kg) and glibenclamide (5 mg/kg) on liver and kidney oxidative stress markers in diabetic rat in STZ-induced diabetic rats. Oxidative stress markers in liver: (<bold>A</bold>) GPx, (<bold>B</bold>) malondialdehyde (MDA) (<bold>C</bold>) glutathione (GSH). In kidney: (<bold>D</bold>) GPx, (<bold>E</bold>) MDA, (<bold>F</bold>) GSH. The values are expressed as mean &#x000b1; SEM. Each value corresponds to a mean of eight animals <sup>###</sup>
<italic>p</italic> &#x002c2; 0.001; comparison of <sup>a</sup>(normal control) vs. <sup>b</sup>(diabetic control) using student <italic>t</italic>-test, * <italic>p</italic> &#x002c2; 0.05, ** <italic>p</italic> &#x002c2; 0.01, *** <italic>p</italic> &#x0003c; 0.001; comparison of <sup>b</sup>(diabetic control) vs. <sup>c</sup>(Glibenclamide and CTN treated groups) using one way ANOVA followed by Dunnett&#x02019;s post hoc multiple comparison test.</p></caption><graphic xlink:href="molecules-26-00137-g005"/></fig><fig id="molecules-26-00137-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Effects of catechin (2, 5, 10, 15, 30 and 50 mg/kg) and glibenclamide (5 mg/kg) on pancreas histopathology studies in STZ-induced diabetic rats (H&#x00026;E staining; 40&#x000d7;, scale bar = 100 &#x003bc;m): (<bold>A</bold>) control group; (<bold>B</bold>) diabetic control group; (<bold>C</bold>) glibenclamide (5 mg/kg/overly) treated group; (<bold>D</bold>,<bold>E</bold>) CTN (2, 5 mg/kg/orally) treated group; (<bold>F</bold>,<bold>G</bold>) CTN (10, 15 mg/kg/orally) treated groups (<bold>H</bold>,<bold>I</bold>) CTN (30 and 50 mg/kg/orally) treated group.</p></caption><graphic xlink:href="molecules-26-00137-g006"/></fig></floats-group></article>